Vaccination therapy in prostate cancer

Andrea Marrari, Manuela Iero, Lorenzo Pilla, Sergio Villa, Roberto Salvioni, Riccardo Valdagni, Giorgio Parmiani, Licia Rivoltini

Research output: Contribution to journalArticlepeer-review


Radical prostatectomy and radiation therapy provide excellent localized prostate cancer (PC) control. Although the majority of prostate carcinoma is nowadays diagnosed at early stages with favourable risk features, in patients up to 30-40% it recurs within 10 years. Furthermore, the lack of effective therapies, once prostate carcinoma becomes refractory to androgen deprivation, mandates the development of alternative therapeutic options. There is a growing interest in harnessing the potency and specificity of anti-tumour immunity through the generation of fully competent dendritic cells and tumour reactive effector lymphocytes. Several strategies to treat or prevent the development of metastatic PC have been explored in clinical trials and are summarized in this review, considering also the feasibility and safety of these approaches. In some cases clinical responses were achieved showing that vaccine-primed T cells induced anti-tumour activity in vivo. The present findings and perspectives of the immunologic interventions in PC patients will be discussed.

Original languageEnglish
Pages (from-to)429-445
Number of pages17
JournalCancer Immunology, Immunotherapy
Issue number4
Publication statusPublished - Apr 2007


  • Androgen deprivation therapy
  • Antigens
  • Cancer vaccine
  • Prostate cancer
  • Radiotherapy
  • Tumour immunity

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology


Dive into the research topics of 'Vaccination therapy in prostate cancer'. Together they form a unique fingerprint.

Cite this